



# WIN SYMPOSIUM 29-30 October 2022 Barcelona, Spain




## INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY: A WINNING STRATEGY

**Saturday October 29**




### WELCOME AND OPENING REMARKS

	<b>Welcome and opening remarks</b>	Richard L. Schilsky	Chairman WIN Consortium, Villejuif, France
		Josep Taberero	Vice-Chairman WIN Consortium, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
	<b>Opening Keynote Lecture</b> Re-imagining the (r)evolution in the Precision Oncology paradigm: the future is now	Vivek Subbiah	The University of Texas, MD Anderson Cancer Center, Houston, USA

### SESSION 1 - BEYOND DNA TESTING: THE PLACE OF TRANSCRIPTOMICS IN PRECISION ONCOLOGY

	<b>Keynote Lecture</b> Expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy	Louis M. Staudt	National Cancer Institute (NCI), Bethesda, USA
	<b>Keynote Lecture</b> Functional genomics to identify cancer vulnerabilities	René Bernards	Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
	Accelerating precision oncology using multi-omics and AI	Olivier Elemento	Weill Cornell Medicine, New York, USA






*Coffee break, networking*

	Modeling gene regulatory processes to understand cancer and identify therapies	John Quackenbush	Harvard T.H. Chan School of Public Health, Boston, USA
	SIMS and Digital Display Precision Predictor algorithms	Vladimir Lazar	WIN Consortium, Villejuif, France
	Harnessing a synthetic lethality analysis for patient stratification: key role of transcriptomics	Eytan Rupp	National Institute of Health (NIH), Bethesda, USA

Panel Discussion

*Lunch, poster viewing and networking*

### SESSION 2 – INNOVATION IN CLINICAL TRIALS TO ENABLE FUTURE EFFICIENT TREATMENTS

	<b>Keynote opening Lecture</b> Bringing single cell analyses to the clinics	Andrea Califano	Columbia University Medical Center, New York, USA
	<b>Keynote lecture</b> Identifying new uses for approved, targeted drugs: Updates from the ASCO TAPUR study	Richard L. Schilsky	WIN Consortium, Villejuif, France
	Genomic and transcriptomic signatures and innovation in CRC cancers	Josep Taberero	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
	Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses	Jean-François Martini	Pfizer, Inc., San Diego, USA
	IO in combination: the SPRING tri-therapy approach	Benjamin Solomon	Avera Cancer Institute, Sioux Falls, USA

*Coffee break, networking*

Satellite Symposium

*Poster viewing  
Welcome reception  
Symposium Dinner*


**SESSION 3 – DISRUPTIVE CONCEPTS AND METHODOLOGICAL INNOVATIONS IN NSCLC: MEET THE EXPERTS**

	<b>Keynote lecture</b> Overview of advances in lung cancer	Enriqueta Felip	Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
	From chest x ray to AI-assisted lung cancer screening and early detection program in Israel	Amir Onn	Sheba Medical Center, Ramat Gan, Israel
	Individualized surgical treatment strategy for early-stage lung cancer: Translation of knowledge	Haiquan Chen	Fudan University, Shanghai, China
	Neoadjuvant and adjuvant strategies in NSCLC	Jair Bar	Sheba Medical Center, Ramat Gan, Israel
	New drugs for SCLC	Pilar Garrido	Universidad de Alcalá, Madrid, Spain

Panel Discussion and Q&A from the audience

*Coffee Break, networking*







**SESSION 4 - WIN FIRST INTERNATIONAL MOLECULAR TUMOR BOARD: A STRATEGIC PLACE IN ADVANCING PRECISION ONCOLOGY**

	<b>First WIN International Molecular Tumor Board</b> Introduction Patients' cases presentation by investigators. Discussion and treatment recommendation.	Moderator Razelle Kurzrock	WIN Consortium, Villejuif, France
--	---	-------------------------------	-----------------------------------

Panel Discussion and Q&A from the audience

*Lunch, poster viewing and networking*

**SESSION 5 – WHAT IS NEW IN BREAST, CRC, HEAD & NECK and PEDIATRIC CANCERS?**

	<b>Opening Keynote Lecture</b> The BIG AURORA molecular screening program for metastatic breast cancer: first results	Martine Piccart	Institut Jules Bordet, Brussels, Belgium
	<b>Keynote Lecture</b> Novel CRC insights based on combined genomic and transcriptomic data at both bulk and single cell level, leading to new therapeutically relevant CRC classification	Sabine Tejpar	University of Leuven, Belgium
	Serial profiling in metastatic CRC; beyond the tip of the iceberg	Gerald Batist	Segal Cancer Centre, Lady Davis Institute at the JGH, McGill University, Montréal, Canada
	Proteogenomic analysis of triple negative breast cancer (TNBC) response to neoadjuvant chemotherapy	Matthew Ellis	AstraZeneca, USA
	Novel strategies in head & neck cancers	Christophe Le Tourneau	Institut Curie, Paris, France
	Pediatric European Precision Cancer Medicine Program - Facing cancer complexity	Birgit Geoerger	Gustave Roussy, Villejuif, France ITCC

Panel Discussion and Q&A from the audience

**BEST TWO POSTERS' PRESENTATIONS AND AWARDS**

Josep Tabernero, Vice-Chairman WIN Consortium, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain  
Amir Onn, Head of the Standard Operating Procedures and Repository Committee, WIN Consortium;  
Chair, Institute of Pulmonary Medicine, Sheba Medical Center, Israel

**CONCLUSIONS**

Richard L. Schilsky, Chairman WIN Consortium